title: Eliminating encephalitogenic T cells without undermining protective immunity.
abstract: The current clinical approach for treating autoimmune diseases is to broadly blunt immune responses as a means of preventing autoimmune pathology. Among the major side effects of this strategy are depressed beneficial immunity and increased rates of infections and tumors. Using the experimental autoimmune encephalomyelitis model for human multiple sclerosis, we report a novel alternative approach for purging autoreactive T cells that spares beneficial immunity. The moderate and temporally limited use of etoposide, a topoisomerase inhibitor, to eliminate encephalitogenic T cells significantly reduces the onset and severity of experimental autoimmune encephalomyelitis, dampens cytokine production and overall pathology, while dramatically limiting the off-target effects on naive and memory adaptive immunity. Etoposide-treated mice show no or significantly ameliorated pathology with reduced antigenic spread, yet have normal T cell and T-dependent B cell responses to de novo antigenic challenges as well as unimpaired memory T cell responses to viral rechallenge. Thus, etoposide therapy can selectively ablate effector T cells and limit pathology in an animal model of autoimmunity while sparing protective immune responses. This strategy could lead to novel approaches for the treatment of autoimmune diseases with both enhanced efficacy and decreased treatment-associated morbidities.
authors.affiliation: Division of Immunobiology, Cincinnati Children's Research Foundation, Cincinnati, OH 45229;
authors.forename: Jonathan P
authors.initials: JP
authors.lastname: McNally
authors.forename: Eileen E
authors.initials: EE
authors.lastname: Elfers
authors.forename: Catherine E
authors.initials: CE
authors.lastname: Terrell
authors.forename: Eli
authors.initials: E
authors.lastname: Grunblatt
authors.forename: David A
authors.initials: DA
authors.lastname: Hildeman
authors.forename: Michael B
authors.initials: MB
authors.lastname: Jordan
authors.forename: Jonathan D
authors.initials: JD
authors.lastname: Katz
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D001402:B-Lymphocytes / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D018450:Disease Progression; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D005047:Etoposide / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D007156:Immunologic Memory; D008213:Lymphocyte Activation / Q000187:drug effects; D008212:Lymphocyte Depletion; D008217:Lymphocytic choriomeningitis virus / Q000276:immunology; D051379:Mice; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D012008:Recurrence; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
chemical_list: D005047:Etoposide